ArticleHealth science reports2025
Advancing Hematopoietic Stem Cell Transplantation (HSCT) in Africa: A Pathway to Curing Hematological Disorders.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Hematopoietic Cell Transplantation for Sickle Cell Disease.Children (Basel, Switzerland) · 2026Review
- Beyond hematopoietic stem cell transplantation: positioning Africa for scalable uptake of innovative sickle cell therapies.BMJ global health · 2026Article
- Splenectomy revisited in Wiskott-Aldrich syndrome in the era of HSCT and gene therapy: a bridge, a rescue, or simply obsolete?Frontiers in immunology · 2026Review
- Advancing Hematopoietic Stem Cell Transplantation (HSCT) in Africa: A Pathway to Curing Hematological Disorders.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematopoietic stem cell transplantation (HSCT) offers a curative option for numerous hematological disorders, notably sickle cell disease and thalassemia, which are highly prevalent in Africa. Despite its potential, access to HSCT remains limited due to infrastructural, economic, and socio-cultural challenges across the continent. Methods: This review synthesizes current literature and reports on the status of HSCT in Africa, analyzing data from existing transplant centers, national registries, and peer-reviewed studies to assess progress, challenges, and prospects for expanding HSCT services. Results: Out of 54 African countries, only seven perform HSCT, with considerable disparities in the number of procedures, donor availability, and infrastructure. Major barriers include inadequate healthcare infrastructure, limited trained personnel, scarcity of donors, high costs, cultural misconceptions, and poor documentation. Notably, progress has been made in Nigeria, Egypt, Morocco, Tunisia, South Africa, Tanzania and Algeria, but the overall transplant rate remains low. Emerging strategies such as regional collaborations, the development of African-specific donor registries, and technological innovations are being explored to improve access and outcomes. Conclusion: While HSCT in Africa is still in its infancy, strategic investments in infrastructure, capacity building, donor registry development, and regional cooperation hold promise for broader access. Integrating technological advances and policy support can accelerate progress, transforming HSCT into a sustainable, accessible curative therapy for hematological disorders across the continent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.